This may be considered reassuring with regards to the risk of increased susceptibility to intestinal infection and inflammation that could be associated with the use of anti-GARP:TGF-β1 mAbs for cancer immunotherapy. The gene discussed is TGFB1; the disease is digestive system infectious disorder.